Видео с ютуба Elacestrant

Elacestrant: A New Weapon Against Advanced Estrogen Receptor-Positive Breast Cancer

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

ERADICATE: elacestrant plus trastuzumab deruxtecan in HR+/HER2-low mBC

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer

Breast Cancer Breakthroughs: Dr. Donald McDonnell explains how elacestrant was discovered in his lab

Elacestrant in ER+/HER2- mBC with ESR1-mut tumors: Overview of the EMERALD subgroup analyses

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer

Можно ли принимать таблетки вместо инъекций при раке груди?

ER+ metastatic breast cancer: Elacestrant and beyond

Oral SERDs Explained: A New Option for Breast Cancer Patients

Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer

Elacestrant in ER+/HER2- mBC: Overview of the EMERALD subgroup analysis

EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani

Elacestrant shows improved PFS in patients with ER-positive/HER2-negative metastatic breast cancer

Elacestrant

Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBC

Tumori: oncologa Del Mastro, ‘elacestrant passo avanti in cura cancro seno metastatico’